Region — International. Neutral scientific reference — not offered for sale here.
Research reference — not for sale
Selank
Clead outcome
Generalized anxiety disorder (on-label in…
grades vary by outcome ↓
Peptide
also called — Selank · TP-7 (Tuftsin-Proline-Glycine-Proline) · a tuftsin analog · sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) (MW ~752 Da). INCI: none
anxiolytic (approved: GAD)neuro / cognitive (secondary)immunomodulatory (research context)
Reference entry — not sold here. Like Semax (#41), Selank is an approved prescription drug in Russia — the anxiety-focused sibling to Semax's cognition focus. Credit its real standing; flag that its evidence is Russian and not independently replicated. No dosing published here.
In brief
Selank is a synthetic analog of the immune peptide tuftsin, developed in Russia (same institute and lead investigator as Semax) and approved there as a prescription anxiolytic for generalized anxiety disorder. Its defining feature is anxiety relief without sedation, tolerance, or dependence — a profile no Western-approved anxiolytic achieves cleanly. But its evidence is predominantly Russian and not independently replicated to Western standards, and it is not FDA/EMA approved. It is the anxiety-focused counterpart to Semax (#41), the cognition-focused one.
Legal standing, by region
European Union
Not approved
Not approved; not eligible for magistral/officinal compounding.
United States
Not FDA-approved (gray-market)
Not FDA-approved. Gray-market / research-chemical use; its compounding status falls within the ongoing 2023–2026 FDA peptide review — confirm current status.
International
Approval limited to Russia/CIS
Approval limited to Russia/CIS.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
OutcomeEvidence base · effectGrade
Generalized anxiety disorder (on-label in Russia)
Strongest use, but Russian-only, no Western replication; methodology varies from FDA/EMA standards
Russian RCTs — anxiolytic efficacy compared to benzodiazepines (e.g. medazepam), without sedation · Meaningful anxiety reduction
CAnxiolytic mechanism (GABA / enkephalin / BDNF)
Animal/mechanistic; human translation is Russian-only
Preclinical (rodent) + Russian mechanistic work · Multi-target, well-characterised
BCognitive / nootropic (secondary)
Weaker than the anxiety use; often a downstream effect of reduced anxiety
Extrapolated + limited data · Secondary to anxiolysis
DImmune / antiviral (tuftsin heritage)
Preclinical; from its tuftsin origin
Preclinical (cytokine regulation; antiviral fragments) · Suggestive
CGeneral "stress / focus" (biohacker use)
Not the approved use
Extrapolated · Suggestive
DSafety
No sedation, tolerance, or dependence — a genuine advantage over benzodiazepines; long-term / Western data limited
Approved drug (Russia), broad clinical use · Notably clean
—Disclosure
Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.
Evidence changes
Get notified if this changes
We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Selank changes - nothing else.
Identity
a synthetic heptapeptide (7 amino acids, < 40 aa → peptide) — the endogenous immune peptide tuftsin (Thr-Lys-Pro-Arg) extended with a C-terminal Pro-Gly-Pro tail for metabolic stability. (Note the same Pro-Gly-Pro stabilisation trick used in Semax — a signature of this Russian peptide programme.)
Development & history
- Engineered in the 1990s at the Institute of Molecular Genetics, Russian Academy of Sciences — the same institute as Semax, with Nikolai F. Myasoedov as a principal investigator for both. The design took the immune tetrapeptide tuftsin and stabilised it into the heptapeptide Selank.
- Approved in Russia as a prescription anxiolytic (and nootropic) for generalized anxiety disorder (GAD) and neurasthenia, given intranasally. Its "an immune peptide became an anxiolytic" origin is genuinely part of its identity — the tuftsin heritage is why it also carries immunomodulatory/antiviral activity.
Mechanism (as proposed)
Selank does not act through a single receptor. It is proposed to allosterically modulate GABA-A receptors without binding the benzodiazepine site (hence anxiolysis without the sedation/dependence of benzodiazepines), inhibit enkephalinase (prolonging endogenous enkephalins — the same enzyme family Semax engages), modulate serotonin metabolism, upregulate hippocampal BDNF, and regulate inflammatory cytokines (its tuftsin-derived immune arm). This multi-target profile is offered as the explanation for anxiety relief without single-target trade-offs.
Chemical identifiers
Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.
InChIKeyJTDTXGMXNXBGBZ-YVHUGQOKSA-N
SMILESC[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N3CCC[C@H]3C(=O)O)N)O
via PubChem exact-name match (Selank) · high confidence
Sources — 4 cited
01(Institute of Molecular Genetics, RAS — Selank development; Myasoedov and colleagues; Russian regulatory registration.)
02(Russian clinical trials of Selank in generalized anxiety disorder / neurasthenia — efficacy vs benzodiazepines; cite specific trials before publishing.)
03Agniullin YaV, Myasoedov NF, et al. (Selank effects on the hippocampal transcription profile — mechanism.)
04Tuftsin / immunomodulation literature (for the antiviral/cytokine arm).
Updated 2026-07-04
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
VallydiaA neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
Region — International
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.